News

Women with early-stage breast cancer who were treated with breast-conserving therapy (BCT) and radiation had improved survival after 10 years compared with those who had a mastectomy without radiation, according to research findings presented recently at the 2015 SABCS.

The incidence of Hodgkin lymphoma (HL) in women typically precedes and covers prime childbearing years, but a new study has found that pregnancy does not increase the risk of relapse among women in remission.

It is estimated that 1 million new cases are diagnosed in the world each year, and more than 723,000 deaths occur annually.

The non-alcohol formulation of docetaxel (Docetaxel Injection) has been approved by the FDA as treatment for patients with breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, and head and neck cancer.

Patients who self-reported their symptoms using a web-based system while undergoing chemotherapy had better health-related quality of life, fewer emergency room (ER) visits, remained on treatment longer, and survived longer than patients who received usual care.

Practitioners awaiting guidelines for the optimum support of breast cancer survivors now have a resource to turn to with the release of a new clinical oncology breast cancer survivorship care guideline, a collaborative effort of ASCO and ACS.

A recent study has found that the majority of women at an increased risk of developing breast cancer either refuse or do not adhere to preventive treatment.

For patients with epithelial ovarian cancer, adjuvant hormone therapy (AHT) proved to be safe and reduced the risk of death by 37%, according to findings of a 24-year study recently published in the Journal of Clinical Oncology.

Lung cancer remains the leading cause of cancer mortality, killing more Americans than breast, colon, and prostate cancer combined—and Kentucky is the epicenter of lung cancer in the United States.

ASH highlights five recommendations from other organizations.

The FDA has approved the expanded indication for single-agent pembrolizumab (Keytruda) to include the frontline treatment of patients with unresectable metastatic melanoma regardless of BRAF status.

This annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma

CancerCare has achieved its goal of enrolling more than 3,000 adults who have been diagnosed with cancer into its landmark Patient Access and Engagement study.

Leukemia & Lymphoma Society-Supported Research Highlighted at American Society of Hematology (ASH) Meeting

Now FDA-approved for treatment of overdoses of fluorouracil or capecitabine.

The FDA has approved bendamustine hydrochloride (Bendeka) injection for the treatment of chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin lymphoma (NHL).

After immigrating from El Salvador at age 19, 22-year-old Marvin Arrivillaga had completed his requirements for joining the U.S. Navy and was preparing to leave for basic training.

For women with heavily treated HER2-positive breast cancer, T-DM1 (ado-trastuzumab emtansine, Kadcyla) was found to improve overall survival (OS) by 7 months according to updated data from a phase III trial.

The immunotherapy pembrolizumab (Keytruda) demonstrated on overall response rate (ORR) of 12% in patients with ER-positive, HER2-negative advanced breast cancer in the phase 1b KEYNOTE-028 trial, marking the second early-stage trial to show antitumor activity with this agent in breast cancer.

The ALK-inhibitor alectinib (Alecensa) was granted accelerated approval by the FDA for patients with metastatic non-small-cell lung cancer (NSCLC) whose disease progressed on crizotinib (Xalkori).

A new study has shown that overall quality of life is similar among patients taking tamoxifen or anastrozole, but patient reports on their hot flashes, night sweats, vaginal dryness, and joint pain can help illuminate which therapy may be right for a particular woman. And, the analysis shows, age matters.

The FDA has approved uridine triacetate (Vistogard) for the emergency treatment of adult and pediatric patients who had severe or life-threatening toxicities within 4 days of treatment following an overdose of 5-fluorouracil (5-FU) or capecitabine.

The immunotherapy agent avelumab yielded encouraging overall response rates (ORR) for patients with PD-L1–positive metastatic breast cancer and had an acceptable safety profile, according to findings reported at the San Antonio Breast Cancer Symposium (SABCS).

I will never forget the emotions – mostly disbelief and fear – that arose when I arrived at the cancer center.

Denosumab not only promotes bone health, it confers a survival advantage, according to data from a follow-up analysis of the ABCSG-18 trial reported at the 2015 San Antonio Breast Cancer Symposium (SABCS).

Roger Lo, MD, PhD, UCLA Jonsson Comprehensive Cancer Center, discusses the evolution of metastatic melanoma during therapy.

The FDA has cleared for marketing the nation’s first cooling cap—the Dignitana DigniCap Cooling System—to reduce the severity and frequency of hair loss in patients receiving chemotherapy for breast cancer.

Entering through the giant, inflatable colon, dozens of patients, caregivers, family members and providers gathered at the Georgetown University Hotel and Conference Center in Washington, DC, December 5 for the symposium, “Fighting a Smarter War Against Cancer.”